Annual report pursuant to Section 13 and 15(d)

1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.19.2
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Accumulated deficit $ (105,652,433) $ (99,457,714)
Noncontrolling interests (126,031) (101,246)
Cash equivalents 0 0
Cash balances over insured amount 3,724,000  
Asset impairment charges $ 0 $ 0
Shares considered antidilutive 6,566,766 7,050,049
Amortization of deferred financing costs $ 0 $ 0
Research and development expenses 896,000 586,000
National Institute of Health [Member] | Breast Cancer Grant [Member]    
Contract revenue 80,000  
National Institute of Health [Member] | Melanoma Cancer Contract [Member]    
Contract revenue $ 149,625 $ 149,625
ESI [Member]    
Equity ownership percentage 80.00% 80.00%
Noncontrolling interests $ (126,031) $ (101,246)